Article Versions Notes

Matsumoto H, Igarashi C, Tachibana T, Hihara F, Shinada M, Waki A, Yoshida S, Naito K, Kurihara H, Ueno M, et al. Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET. Pharmaceutics. 2022; 14(9):1928. https://doi.org/10.3390/pharmaceutics14091928

Matsumoto, Hiroki, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Mitsuhiro Shinada, Atsuo Waki, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno, and et al. 2022. "Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET" Pharmaceutics 14, no. 9: 1928. https://doi.org/10.3390/pharmaceutics14091928

Matsumoto, H., Igarashi, C., Tachibana, T., Hihara, F., Shinada, M., Waki, A., Yoshida, S., Naito, K., Kurihara, H., Ueno, M., Ito, K., Higashi, T., & Yoshii, Y. (2022). Preclinical Safety Evaluation of Intraperitoneally Administered Cu-Conjugated Anti-EGFR Antibody NCAB001 for the Early Diagnosis of Pancreatic Cancer Using PET. Pharmaceutics, 14(9), 1928. https://doi.org/10.3390/pharmaceutics14091928